Docetaxel (DOC) and abiraterone (ABI) in the upfront setting have separately improved clinical outcomes for metastatic hormone-sensitive prostate cancer (mHSPC), but there are no studies comparing drug efficacies or the influence of racial disparities.
Unmarried status is an established risk factor for worse cancer control outcomes in various malignancies. Moreover, several investigators observed worse outcomes in unmarried males, but not in females.
U.S. clinical guidelines recommend that prior to screening for prostate cancer with Prostate Specific Antigen (PSA), men should have an informed discussion about the potential benefits and harms of screening.
Studies describing treatment utilization for castration-resistant prostate cancer (CRPC) are limited. We aimed to describe the treatment utilization of a contemporary population-based CRPC cohort between 2006 and 2016.
The PI3K/mTOR/AKT pathway might represent an intriguing option for treatment of penile cancer (PeCa). We aimed to assess whether members of this pathway might serve as biomarkers and targets for systemic therapy.
Repeat BCG induction remains an option for select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have been investigated.
Less than one-third of bladder cancers are non-pure urothelial carcinoma [with variant histological (VH) or non-urothelial carcinoma (non-UC)] for which no treatment guidelines are available. We aim to evaluate the efficacy of systemic treatments in VH or non-UC bladder cancers.
(UroToday.com) Inducible T-cell co-stimulatory expression is induced on T-cells following T-cell receptor activation and previous studies have demonstrated that inducible T-cell co-stimulation is highly expressed in urothelial carcinoma across all stages of disease.
Charles Ryan: Hello from ASCO 2021. Chuck Ryan here from the University of Minnesota, and I’m talking today with Fred Saad who is the Head of Urology and the Medical Director of the Interdisciplinary Urology Oncology Group at the University Hospital of Montreal, where he’s also the Director of Prostate Cancer Research and Professor of […]
Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to have here with me today, Dr. Sia Daneshmand, who is the Director of Urologic Oncology and a Professor of Urology at the University of Southern California. Thank […]
